A Study to Evaluate the Efficacy and Safety of AD-223
Phase 3
Recruiting
- Conditions
- Hypertension,Essential
- Interventions
- Drug: AD-223ADrug: AD-223CDrug: AD-223BDrug: AD-223B PlaceboDrug: AD-223A PlaceboDrug: AD-223C Placebo
- Registration Number
- NCT06052748
- Lead Sponsor
- Addpharma Inc.
- Brief Summary
The purpose of this study is to evaluate the efficacy and safety of AD-223
- Detailed Description
Condition or disease : hypertension
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 486
Inclusion Criteria
- Signed informed consent
- Other inclusions applied
Read More
Exclusion Criteria
- Orthostatic hypotension with symptom
- Other exclusions applied
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Test group AD-223A AD-223A+AD-223B+AD-223C Placebo Test group AD-223B AD-223A+AD-223B+AD-223C Placebo Test group AD-223C Placebo AD-223A+AD-223B+AD-223C Placebo Control group 1 AD-223A AD-223A+AD-223B Placebo+AD-223C Placebo Control group 1 AD-223B Placebo AD-223A+AD-223B Placebo+AD-223C Placebo Control group 1 AD-223C Placebo AD-223A+AD-223B Placebo+AD-223C Placebo Control group 2 AD-223B AD-223A Placebo+AD-223B+AD-223C Placebo Control group 2 AD-223A Placebo AD-223A Placebo+AD-223B+AD-223C Placebo Control group 2 AD-223C Placebo AD-223A Placebo+AD-223B+AD-223C Placebo Control group 3 AD-223C AD-223A Placebo+AD-223B Placebo+AD-223C Control group 3 AD-223A Placebo AD-223A Placebo+AD-223B Placebo+AD-223C Control group 3 AD-223B Placebo AD-223A Placebo+AD-223B Placebo+AD-223C
- Primary Outcome Measures
Name Time Method Change rate of MSSBP Baseline, Week 8 Change from baseline in mean sitting systolic blood pressure
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hanyang University Hospital
🇰🇷Seoul, Korea, Republic of